メニュー
Generate comprehensive compound profiles including structure, properties, bioactivity, and development status. Use for drug analysis, SAR studies, and competitive profiling. Keywords: compound, drug, molecule, structure, SMILES, bioactivity, IC50
Codex または Claude でインストール この Prompt をコピーして Codex、Claude、または他のアシスタントに貼り付けると、Skill ページを確認してインストールできます。
SOC 職業分類に基づく
Global drug development pipeline tracking by disease, target, mechanism, or company. Use for competitive intelligence, opportunity identification, and trend analysis. Keywords: pipeline, drug development, clinical trials, R&D tracking, competitive landscape
Structure-based similarity search and scaffold analysis for drug discovery. Use for lead hopping, scaffold morphing, and chemical space exploration. Keywords: similarity search, scaffold hopping, chemical space, fingerprint, Tanimoto
Analyze target competitive landscape including existing drugs, pipeline companies, differentiation opportunities, and market maturity assessment. Keywords: target competition, landscape, differentiation, pipeline analysis, market share
Target safety assessment including known toxicities, essentiality, and off-target concerns. Use for early safety risk evaluation and target selection. Keywords: target safety, toxicity, essential gene, knockout, safety risks
Comprehensive target validation assessing druggability, disease association strength, tractability, and competitive landscape. Use for go/no-go decisions on target selection. Keywords: target validation, druggability, tractability, disease association, genetic validation
ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) prediction for drug candidates. Use for assessing drug-likeness, PK properties, and safety risks early in drug discovery. Keywords: ADMET, PK, toxicity, drug-likeness, DILI, hERG, bioavailability
| name | compound-profile |
| description | Generate comprehensive compound profiles including structure, properties, bioactivity, and development status. Use for drug analysis, SAR studies, and competitive profiling. Keywords: compound, drug, molecule, structure, SMILES, bioactivity, IC50 |
| category | Compound Analysis |
| tags | ["compound","drug","structure","bioactivity","chembl"] |
| version | 1.0.0 |
| author | Drug Discovery Team |
| dependencies | ["chembl-database","pubchem-database","drugbank-database"] |
Comprehensive compound analysis for drug discovery and medicinal chemistry.
/compound erlotinib
/compound-profile CC1=CC=C(C=C1)CNC(=O)C1=NC=C(C=C1)N
Analyze osimertinib properties and bioactivity
Compare gefitinib, erlotinib, afatinib profiles
| Section | Description | Data Source |
|---|---|---|
| Basic Info | Name, type, status, company | ChEMBL, DrugBank |
| Structure | SMILES, InChI, molecular weight | PubChem, ChEMBL |
| Properties | LogP, HBD, HBA, TPSA, RO5 | Calculated, PubChem |
| Bioactivity | Target affinity, IC50, Ki | ChEMBL, BindingDB |
| Development | Phase, indications, status | Drugs@FDA |
| Similar Compounds | Structure similarity search | ChEMBL |
| Safety | Known toxicity, warnings | SIDER, PubChem |
# Compound Profile: Erlotinib
## Executive Summary
Erlotinib is a first-generation EGFR TKI approved for NSCLC (2004).
Key characteristics: Oral bioavailability, good brain penetration,
resistance mutations limit long-term efficacy.
## Basic Information
| Field | Value |
|-------|-------|
| Name | Erlotinib |
| Brand Names | Tarceva |
| ChEMBL ID | CHEMBL880 |
| Type | Small molecule |
| Class | Kinase inhibitor |
| Status | Approved |
| Approval Year | 2004 |
| Company | Astellas (OSI) |
| Indications | NSCLC, pancreatic cancer |
## Structure & Properties
**SMILES:** `COc1cc2nc(Nc3ccc(Oc4ccc(O)cc4)cc3)nc2cc1OC`
| Property | Value | Rule of 5 Check |
|----------|-------|----------------|
| MW | 393.4 Da | ✓ (<500) |
| LogP | 3.1 | ✓ (<5) |
| HBD | 1 | ✓ (≤5) |
| HBA | 7 | ✓ (≤10) |
| TPSA | 76.3 Ų | ✓ (<140) |
| Rotatable Bonds | 6 | |
## Bioactivity
| Target | Type | Affinity | Units |
|--------|------|----------|-------|
| EGFR | IC50 | 0.5 | nM |
| ERBB2 | IC50 | 1200 | nM |
| LCK | IC50 | 5 | nM |
## Development History
| Year | Milestone |
|------|-----------|
| 2004 | FDA Approval (NSCLC) |
| 2005 | EMEA Approval |
| 2010 | Pancreatic cancer approval |
| 2011 | Generic launch (US) |
## Similar Compounds
| Compound | Similarity | Difference |
|----------|------------|------------|
| Gefitinib | 85% | Different core scaffold |
| Afatinib | 72% | Irreversible binder |
| Osimertinib | 68% | 3rd-gen, mutant-selective |
| Icotinib | 82% | China-approved analog |
## Safety Profile
**Common AEs:** Rash, diarrhea, fatigue, anorexia
**Boxed Warning:** Interstitial lung disease
**Contraindications:** Hypersensitivity to erlotinib
## Patent Status
| Patent | Number | Expiry |
|--------|---------|--------|
| Base patent | US5747498 | 2019 (expired) |
| Formulation | US6943129 | 2020 |
| Method of use | US6900221 | 2021 |
/compound erlotinib
/compound-profile sotorasib
/compound "CC1=CC=C(C=C1)CNC(=O)C1=NC=C(C=C1)N"
/compound-profile SMILES
Compare compounds erlotinib, gefitinib, afatinib
Analyze bioactivity across EGFR inhibitors
/compound erlotinib --focus properties
Analyze drug-likeness of this compound
Check Lipinski rule of 5 violations
# Fetch compound by name
python scripts/fetch_compound_data.py erlotinib --output compound.json
# Fetch by SMILES
python scripts/fetch_compound_data.py --smiles "CC1=CC=C..." -o data.json
# Similarity search
python scripts/fetch_compound_data.py --similar CHEMBL880 --threshold 0.7
# Bioactivity summary
python scripts/fetch_compound_data.py erlotinib --bioactivity -o activity.json
# Structure search
python scripts/fetch_compound_data.py --scaffold quinazoline --limit 20
pip install requests pandas rdkit
| Pitfall | Solution |
|---|---|
| Name ambiguity | Use ChEMBL ID when possible |
| Stereochemistry | SMILES may not capture isomerism |
| Outdated data | Check multiple sources |
| Salt forms | API may have multiple entries |
| Tautomerism | Different SMILES for same structure |